IR Partners supported Faron in the redesign of its investor website and press release system

Faron Pharmaceuticals is an internationally listed biotechnology company traded on the AIM market of the London Stock Exchange and the Nasdaq First North Growth Market on the Helsinki Stock Exchange. Listed on two exchanges, Faron wanted to update its investor website and press release distribution to meet the requirements of both the Helsinki Stock Exchange and the London AIM market. The goal was to streamline the company’s investor communications, develop a more user-friendly website structure, and better serve the company’s diverse investor base, particularly Finnish retail investors.

IR Partners ensured that the new investor website had a clear structure, understandable content, and accessible language versions, while also supporting the company’s investor story. At the same time, the company’s press release distribution solutions were also updated: the two separate distribution systems previously in use were replaced with a single modern and efficient press release system that seamlessly serves both marketplaces. As a result of the overhaul, Faron gained a clear and continuously evolving system that strengthens the impact of the company’s investor communications and streamlines internal processes.

“We are very pleased with the result. The project was a major undertaking for the company, but thanks to IR Partners’ implementation, it did not tie up our resources; instead, IR Partners, as our partner, ensured that the project was completed in an agile manner. The overhaul of our investor relations system streamlined our internal processes and increased our efficiency in investor communications. The new website serves our investor community even better than before.” — Paavo Koivisto, Director, Investor Relations and Funding, Faron Pharmaceuticals

Kare Laukkanen

Business Director, IR and Financial Communications, Partner

+358 50 553 9535 kare.laukkanen@irpartners.fi